Form 8-K · Current report
Prologis 8-K, filed Jul 16, 2026
- Filed
- CIK
- 0001045609
- Accession no.
- 0001193125-26-305416
Summary
Prologis announced second-quarter 2026 financial results, reporting total revenues of $2.425 billion and net earnings attributable to common stockholders of $1.061 billion, and provided 2026 guidance for Core FFO of $6.22 to $6.30 per share and net earnings of $4.40 to $4.55 per share.
Key points
- Prologis reported second-quarter 2026 total revenues of $2.425 billion, compared with $2.184 billion in the second quarter of 2025.
- Net earnings attributable to common stockholders were $1.061 billion, or $1.13 per diluted share, compared with $570 million, or $0.61 per diluted share, a year earlier.
- Core FFO attributable to common stockholders/unitholders was $1.559 billion, or $1.63 per diluted share, and AFFO was $1.323 billion.
- Prologis' 2026 guidance includes average occupancy of 95.25% to 95.75% and same-store NOI cash growth of 6.75% to 7.25% on a Prologis Share basis.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition (Prologis, Inc.) and Item 7.01. Regulation FD Disclosure (Prologis, Inc. and Prologis, L.P.). On July 16, 2026, Prologis, Inc., the general partner of Prologis, L.P., issued a press release announcing second quarter 2026 financial results. A copy of the supplemental information as well as the press release is furnished with this report as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.